Autopsy report · NCT06123858

Non-alcoholic Steatohepatitis Registry Platform Study

“Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 1,122 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

NASH With Fibrosis

Participants

1,122

Sites

16

Countries

China

Trials that died the same way

• CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  “Sponsor Decision - Pipeline Reprioritization” (74% match in meaning)
• IMM60 and Pembrolizumab in Melanoma and NSCLC
  “Prioritization of other pipeline assets. No safety or efficacy issues were observed.” (61% match in meaning)
• Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
  “sponsor decision to cancel project before enrollment.” (60% match in meaning)
• The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
  “Sponsor Decision to discontinue long-term follow-up” (59% match in meaning)
• PRedIcting MEniscal Tears Outcomes After Physical Therapy Treatment
  “Financial support for the project has been discontinued.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.